Xunbo Jin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xunbo Jin has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Xiude Chen
Department of Urology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China
2 shared publications - Chengjun Lai
Department of Urology, Qingyun County People Hospital, Dezhou, China
1 shared publication Taiguo Qi
Department of Urology, Cheeloo College of Medicine, Shandong Provincial Hospital, Shandong University, Jinan, China
1 shared publication- Taiguo Qi
Department of Urology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China
1 shared publication Xia Qi
Department of Urology, The Second Affiliated Hospital Affiliated to Shandong First Medical University, Taian, China
1 shared publication- Yaqin Li
Department of Urology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China
1 shared publication
Latest Publications
- 13 January 2021
- Published by Springer Nature in Urolithiasis
- Vol. 49 (4) , 367-375
The predictive and diagnostic ability of IL-6 for postoperative urosepsis in patients undergoing percutaneous nephrolithotomy
The aim of this study is to investigate the predictive and diagnostic ability of interleukin-6 (IL-6) for postoperative urosepsis in patients undergoing percutaneous nephrolithotomy (PCNL). 90 patients undergoing PCNL between April 2019 and September 2019 were studied. 16 patients progressed to urosepsis (EXP1 group, n = 16) and 74 patients did not (CON group, n = 74); demographic and perioperative data were compared between these two groups. 25 patients who progressed to postoperative urosepsis without receiving the test of IL-6 between March 2018 and March 2019 were enrolled (EXP2 group, n = 25); demographic and perioperative data were compared between EXP1 group and EXP2 group. Compared with CON group, EXP1 group showed higher serum levels of IL-6 (p < 0.001) and neutrophil (p < 0.001) at postoperative hour two; higher serum levels of IL-6 (p < 0.001), procalcitonin (PCT) (p < 0.05), white blood cell (WBC) (p < 0.05), and neutrophil (p < 0.001) on postoperative day one; higher serum levels of PCT (p < 0.05) and WBC (p < 0.05) on postoperative day three. ROC curves showed IL-6 (AUC = 1.000) at postoperative hour two and PCT (AUC = 0.954) on postoperative day three. Compared with EXP2 group, EXP1 group showed shorter time to intervene (p < 0.001), a shorter postoperative hospital stay (p < 0.001), and a lower incidence rate of severe urosepsis (p < 0.05). There were different diagnostic abilities of IL-6, PCT, WBC, and neutrophil for postoperative urosepsis at different time points, and IL-6 was greatly valuable as a predictive and early diagnosing biomarker for postoperative urosepsis in patients undergoing PCNL at postoperative hour two and on postoperative day one.
- 13 January 2021
- Published by Springer Nature in Urolithiasis
- Vol. 49 (4) , 367-375
The predictive and diagnostic ability of IL-6 for postoperative urosepsis in patients undergoing percutaneous nephrolithotomy
The aim of this study is to investigate the predictive and diagnostic ability of interleukin-6 (IL-6) for postoperative urosepsis in patients undergoing percutaneous nephrolithotomy (PCNL). 90 patients undergoing PCNL between April 2019 and September 2019 were studied. 16 patients progressed to urosepsis (EXP1 group, n = 16) and 74 patients did not (CON group, n = 74); demographic and perioperative data were compared between these two groups. 25 patients who progressed to postoperative urosepsis without receiving the test of IL-6 between March 2018 and March 2019 were enrolled (EXP2 group, n = 25); demographic and perioperative data were compared between EXP1 group and EXP2 group. Compared with CON group, EXP1 group showed higher serum levels of IL-6 (p < 0.001) and neutrophil (p < 0.001) at postoperative hour two; higher serum levels of IL-6 (p < 0.001), procalcitonin (PCT) (p < 0.05), white blood cell (WBC) (p < 0.05), and neutrophil (p < 0.001) on postoperative day one; higher serum levels of PCT (p < 0.05) and WBC (p < 0.05) on postoperative day three. ROC curves showed IL-6 (AUC = 1.000) at postoperative hour two and PCT (AUC = 0.954) on postoperative day three. Compared with EXP2 group, EXP1 group showed shorter time to intervene (p < 0.001), a shorter postoperative hospital stay (p < 0.001), and a lower incidence rate of severe urosepsis (p < 0.05). There were different diagnostic abilities of IL-6, PCT, WBC, and neutrophil for postoperative urosepsis at different time points, and IL-6 was greatly valuable as a predictive and early diagnosing biomarker for postoperative urosepsis in patients undergoing PCNL at postoperative hour two and on postoperative day one.
- Open Access
- 7 January 2021
- Published by Springer Nature in International Urology and Nephrology
- Vol. 53 (4) , 669-677
The retrospective study of perioperative application of dexamethasone and furosemide for postoperative anti-inflammation in patients undergoing percutaneous nephrolithotomy
Objectives: To investigate whether the perioperatively combined application of dexamethasone and furosemide could alleviate the inflammation in patients undergoing percutaneous nephrolithotomy (PCNL). Patients and methods: 147 patients undergoing PCNL between November 2018 and October 2019 were enrolled in the study. 77 patients accepted a single dose of dexamethasone and furosemide administration (EXP group, n = 77), and 70 patients did not (CON group, n = 70). Demographic and perioperative data, inflammatory markers including interleukin-6 (IL-6) and procalcitonin (PCT), and clinical outcomes were compared between the two groups. Results: Compared with the CON group, the incidence rate of urosepsis of the EXP group were significantly lower (11.69% vs. 24.29%, p = 0.046). 3 patients developed severe urosepsis in the EXP group, while 5 patients developed severe urosepsis in the CON group. Compared with those in the CON group, the patients with postoperative urosepsis in the EXP group showed lower serum levels of IL-6 at postoperative hour two (p = 0.045) and at postoperative day one (p = 0.031) and lower serum levels of PCT at postoperative day one (p = 0.015). There was a better clinical outcome of a shorter postoperative hospital stay (p = 0.015) in patients with postoperative urosepsis in the EXP group than in those in the CON group. Conclusion: The perioperatively combined application of dexamethasone and furosemide was beneficial for alleviating postoperative inflammatory reaction and caused a better clinical outcome of a shorter postoperative hospital stay.
- 7 January 2021
- Published by Springer Nature in International Urology and Nephrology
- Vol. 53 (4) , 669-677
Open AccessThe retrospective study of perioperative application of dexamethasone and furosemide for postoperative anti-inflammation in patients undergoing percutaneous nephrolithotomy
Objectives: To investigate whether the perioperatively combined application of dexamethasone and furosemide could alleviate the inflammation in patients undergoing percutaneous nephrolithotomy (PCNL). Patients and methods: 147 patients undergoing PCNL between November 2018 and October 2019 were enrolled in the study. 77 patients accepted a single dose of dexamethasone and furosemide administration (EXP group, n = 77), and 70 patients did not (CON group, n = 70). Demographic and perioperative data, inflammatory markers including interleukin-6 (IL-6) and procalcitonin (PCT), and clinical outcomes were compared between the two groups. Results: Compared with the CON group, the incidence rate of urosepsis of the EXP group were significantly lower (11.69% vs. 24.29%, p = 0.046). 3 patients developed severe urosepsis in the EXP group, while 5 patients developed severe urosepsis in the CON group. Compared with those in the CON group, the patients with postoperative urosepsis in the EXP group showed lower serum levels of IL-6 at postoperative hour two (p = 0.045) and at postoperative day one (p = 0.031) and lower serum levels of PCT at postoperative day one (p = 0.015). There was a better clinical outcome of a shorter postoperative hospital stay (p = 0.015) in patients with postoperative urosepsis in the EXP group than in those in the CON group. Conclusion: The perioperatively combined application of dexamethasone and furosemide was beneficial for alleviating postoperative inflammatory reaction and caused a better clinical outcome of a shorter postoperative hospital stay.